POSFREA (nda203050)- (EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML),EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML))

Generic Name	PALONOSETRON HYDROCHLORIDE	Innovator	AVYXA HOLDINGS
Dosage	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML),EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
ParaIV Filing	No	505(b)2 Filing	Yes
Last Patent Expiry	Expired	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for: • Moderately emetogenic cancer chemotherapy --prevention of acute and delayed nausea and vomiting associated with initial and repeat courses • Highly emetogenic cancer chemotherapy --prevention of acute nausea and vomiting associated with initial and repeat courses • Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	5

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	**	**	-	-	-
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of POSFREA